2022
Hepatic Metastases in Gastrointestinal Stromal Tumors: Oncologic Outcomes with Curative-Intent Hepatectomy, Resection of Treatment-Resistant Disease, and Tyrosine Kinase Inhibitor Therapy Alone
Sutton T, Walker B, Billingsley K, Sheppard B, Corless C, Heinrich M, Mayo S. Hepatic Metastases in Gastrointestinal Stromal Tumors: Oncologic Outcomes with Curative-Intent Hepatectomy, Resection of Treatment-Resistant Disease, and Tyrosine Kinase Inhibitor Therapy Alone. Hepato Pancreato Biliary 2022, 24: s90-s91. DOI: 10.1016/j.hpb.2022.05.170.Peer-Reviewed Original Research
2021
ASO Visual Abstract: The Disease-Free Interval is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor
Sutton T, Walker B, Billingsley K, Sheppard B, Corless C, Heinrich M, Mayo S. ASO Visual Abstract: The Disease-Free Interval is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor. Annals Of Surgical Oncology 2021, 28: 426-427. DOI: 10.1245/s10434-021-10107-w.Peer-Reviewed Original Research
2016
Aggressive approach to hepatic resection and adjuvant tyrosine kinase inhibitor therapy for metastatic gastrointestinal stroma tumors: Outcomes on survival
Pichardo E, Castillo A, Heinrich M, Billingsley K. Aggressive approach to hepatic resection and adjuvant tyrosine kinase inhibitor therapy for metastatic gastrointestinal stroma tumors: Outcomes on survival. Hepato Pancreato Biliary 2016, 18: e171. DOI: 10.1016/j.hpb.2016.02.408.Peer-Reviewed Original Research